Neuronal nicotinic acetylcholine receptors as novel drug targets

Journal of Pharmacology and Experimental Therapeutics

Volumn 292, Issue 2, 2000, Pages 461-467

  Lloyd, G Kenneth ^a   Williams, Michael ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 3 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 3 METHYL 5 (1 METHYL 2 PYRROLIDINYL)ISOXAZOLE; 4 [[2 (1 METHYL 2 PYRROLIDINYL)ETHYL]THIO]PHENOL; 5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; ACETYLCHOLINE; CYSTINE; EPIBATIDINE; N METHYL 4 (3 PYRIDINYL) 3 BUTENAMINE; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR;

ATTENTION DEFICIT DISORDER; COGNITION; DEGENERATIVE DISEASE; DEPRESSION; DRUG TARGETING; EPILEPSY; HUMAN; MOTOR PERFORMANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CHOLINERGIC AGONISTS; DRUG DELIVERY SYSTEMS; FORECASTING; HUMANS; RECEPTORS, NICOTINIC;

EID: 0033960085     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Badio B and Daly JW (1994) Epibatidine, a potent analgetic and nicotinic agonist. Mol Pharmacol 45:563-569.
2. Bannon AW, Decker MW, Holladay MW, Curzon P, Donnelly-Roberts DD, Puttfarcken PS, Bitner RS, Diaz A, Dickenson AH, Porsolt RD, Williams M and Arneric SP (1998) Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science (Wash DC) 289:77-81.
3. Berkovic S, Curtis L and Betrand D (1998) Neuronal nicotinic receptor channel dysfunction in a human epilepsy syndrome, in Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities (Arneric SP and Brioni JD eds) pp 287-306, Wiley-Liss, New York.
4. Bitner RS, Donnelly-Roberts DL, Nikkel AL, Curzon P and Decker MW (1998) ICV infusion of an antisense oligonucleotide against the alpha-4 subunit of the nicotinic acetylcholine receptor attenuates antinociception produced by the nicotinic agonist A-85380 in rat. Soc Neurosci Abstr 24:336.
5. Breslau N (1995) Psychiatric comorbidity of smoking and nicotine dependence. Behav Genet 25:95-103.
6. Buisson B and Bertrand D (1998) Allosteric modulation of neuronal nicotinic acetylcholine-receptors. J Physiol (Paris) 92:89-100.
7. Calkins BM (1989) A meta-analysis of the role of smoking in inflammatory bowel disorder. Dig Dis Sci 34:1841-1854.
8. Changeux JP, Bertrand D, Corringer PJ, Dehaene S, Edelstein S, Lena C, Le Novere N, Marubio L, Picciotto M and Zoli M (1998) Brain nicotinic receptors: Structure and regulation, role in learning and reinforcement. Brain Res Rev 26:198-216.
9. Davis L, Pollock LJ and Stone TT (1932) Visceral pain. Surg Gynecol Obstet 55:418-427.
10. Decker MW, Sullivan JP, Arneric SP and Williams M (1999) Neuronal nicotinic acetylcholine receptors: Novel targets for CNS therapeutics, in Psychopharmacology: Fourth Generation of Progress CD ROM Version ACNP, Lippincott Williams & Wilkins, Baltimore, MD.
11. French AJ, Humbly T, Horner CH, Sofroniew MV and Rattray M (1999) Hippocampal neurotrophin and trk receptor mRNA levels are altered by local administration of nicotine, carbachol and pilocarpine. Mol Brain Res 67:124-136.
12. Ghelardini C, Galeotti N, Barlocco D and Bartolini A (1997) Antinociceptive profile of the new nicotinic agonist DBO-83. Drug Dev Res 40:251-258.
13. Goff DC, Henderson DC and Amico E (1992) Cigarette smoking in schizophrenia: Relationship to psychopathology and medication side effects. Am J Psychiatry 149:1189-1194.
14. Gotti C, Fornasari D and Clementi F (1997) Human neuronal nicotinic receptors. Prog Neurobiol 53:199-237.
15. Henningfield JE and Heishman SJ (1998) Behavioral toxicology of nicotine, in Nicotine Safety and Toxicity (Benowitz NL ed) pp 133-146, Oxford, New York.
16. Holladay MW, Dart MJ and Lynch JK (1997) Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem 40:4169-4194.
17. Kluger R (1996) Ashes to Ashes, Knopf, New York.
18. Le Novere N, Zoli M, Lena C, Ferrari R, Picciotto MR, Merlo-Pich E and Changeuex J-P (1999) Involvement of α6 nicotinic receptor subunit in nicotine-elicited locomotion, demonstrated by in vivo antisense oligonucleotide infusion. Neuroreport 10:2497-2501.
19. Lee PN (1994) Smoking and Alzheimer's disease: A review of the epidemiological evidence. Neuroepidemiology 13:131-144.
20. Lena C and Changeux JP (1993) Allosteric modulators of the nicotinic acetylcholine receptor. Trends Neurosci 16:181-186.
21. Leonard S, Adler LE, Olincy A, Breese CR, Gault J, Ross RG, Lee M, Cawthra E, Nagamoto HT and Freedman R (1998) The role of nicotine and nicotinic receptors in psychotherapy, in Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities (Arneric SP and Brioni JD eds) pp 307-322, Wiley-Liss, New York.
22. Levin ED, Bettergowda C, Blosser J and Gordon J (1999) AR-R17779, an α7 nicotinic agonist improves learning and memory in rats. Behav Pharmacol 10:675-680.
23. Levin ED and Simon BB (1998) Nicotinic acetylcholine involvement in cognitive function in animals. Psychopharmacology 138:217-230.
24. Marubio LM, Arroyo-Jimenz MDM, Cordero-Erausquin M, Lena C, Le Novere N, D'Exaerde ADK, Huchet M, Damaj MI and Changeux JP (1999) Reduced nociception in mice lacking neuronal nicotinic receptor subunits. Nature (Lond) 398:805-810.
25. Menzaghi F, McClure DA and Lloyd GK (1998) Subtype-selective nAChR agonists for the treatment of neurological disorders: SIB-1508Y and SIB-1553A, in Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities (Arneric SP and Brioni JD eds) pp 379-394, Wiley-Liss, New York.
26. Miwa JM, Ibanez-Tallon I, Crabtree GW, Sanchez R, Sali R, Role LW and Heintz N (1999) Lynx1, an endogenous toxin-like modulator of nicotinic acetylcholine receptors in the mammalian CNS. Neuron 23:105-114.
27. Newhouse P, Sundeland T and Tariot P (1988) Intravenous nicotine in Alzheimer's disease: A pilot study. Psychopharmacology 96:171-175.
28. Picciotto MR, Zoli M, Lena C, Bessis A, Lallemand Y, Le Novere N, Vincent P, Pich EM, Brulet P and Changeux JP (1995) Abnormal avoidance learning in mice lacking functional high-affinity nicotine receptors in the brain. Nature (Lond) 374:65-67.
29. Picciotto MR, Zoli M, Rimondini R, Lena C, Marubio LM, Pich EM, Fuxe K and Changeux JP (1998) Acetylcholine receptors containing the β2 subunit are involved in the reinforcing properties of nicotine. Nature (Lond) 391:173-177.
30. Potter A, Corwin J, Lang J, Piasecki M, Lenox R and Newhouse PA (1999) Acute effects of the selective cholinergic channel activator (nicotine agonist) ABT-418 Alzheimer's disease. Psychopharmacology 142:334-342.
31. Prendergast MA, Jackson WJ, Terry AV Jr, Decker MW, Arneric SP and Buccafusco JJ (1998) Central nicotinic receptor agonists ABT-418, ABT-089, and (-)-nicotine reduce distractibility in adult monkeys. Psychopharmacology 136:50-58.
32. Ramirez-Latorre J, Crabtree C, Turner J and Role L (1998) Molecular composition and biophysical characteristics of nicotinic receptors, in Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities (Arneric SP and Brioni JD eds) pp 43-64, Wiley-Liss, New York.
33. Rose JE (1996) Nicotine addiction and treatment. Ann Rev Med 47:493-507.
34. Sacaan AA, Dunlop JL and Lloyd GK (1995) Pharmacological characterization of neuronal acetylcholine gated ion channel receptor-mediated hippocampal norepinephrine and striatal dopamine release from rat brain slices. J Pharmacol Exp Ther 274:224-230.
35. Sahakian B, Jones G, Levy R, Gray J and Warburton D (1989) The effects of nicotine on attention, information processing, and short term memory in patients with dementia of the Alzheimer type. Br J Psychiatr 154:797-800.
36. Sapori M (1998) Immunosuppressive and anti-inflammatory properties of nicotine, in Neuronal Nicotinic Receptors: Pharmacology and Therapeutic Opportunities (Arneric SP and Brioni JD eds) pp 197-210, Wiley-Liss, New York.
37. Schneider JS, Van Velson M, Menzaghi F and Lloyd GK (1998) Effects of the nicotinic acetykholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: Comparison with levodopa treatment. Ann Neurol 43:311-317.
38. Spande TF, Garraffo HM, Edwards MW, Yeh HJC, Pannell L and Daly JW (1992) A new class of alkaloids from a dendrobatid poison frog: A structure for alkaloid 251F. J Am Chem Soc 114:3475-3478.
39. Stitzer ML and de Wit H (1998) Abuse liability of nicotine, in Nicotine Safety and Toxicity (Benowitz NL ed) pp 119-131, Oxford, New York.
40. Thomas GAO, Rhodes J, Mani V, Wlliams GT, Newcombe R, Russell MA and Feyerabend C (1995) Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 332:988-992.
41. Vetter DE, Liberman MC, Mann J, Barhanin J, Boulter J, Brown MC, Saffiote-Kolman J, Heinemann SF and Elgoyhen AB (1999) Role of the α9 nicotinic ACh receptor subunit in the development and function of cochlear efferent innervation. Neuron 23:93-103.
42. Wilens TE, Biederman J, Spencer TJ, Bostic J, Prince J, Monuteaux MC, Soriano J, Fine C, Abrams A, Rater M and Polisner D (1999) A cholinergic agonist for attention deficit hyperactivity disorder. A pilot controlled clinical trial of ABT-418 in adults. Am J Psychiatry 156:1931-1937.
43. Williams M and Arneric SP (1996) Tobacco: Beyond the smokescreen. Dissecting out the therapeutic potential of nicotine. Exp Opin Invest Drugs 5:1035-1045.